REPL Quote, Financials, Valuation and Earnings

Corcept Therapeutics, Inc. has a net margin of -- compared to Replimune Group, Inc.'s net margin of 11.83%. Replimune Group, Inc.'s return on equity of -92.13% beat Corcept Therapeutics, Inc.'s return on equity of 14.97%.

Replimune Group, Inc. has a consensus price target of $12.86, signalling upside risk potential of 52.88%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $67.40 which suggests that it could grow by 58.63%. Given that Corcept Therapeutics, Inc. has higher upside potential than Replimune Group, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Replimune Group, Inc..

Replimune Group, Inc. has a beta of 0.738, which suggesting that the stock is 26.18% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.249, suggesting its less volatile than the S&P 500 by 75.089%.

Replimune Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.

Replimune Group, Inc. quarterly revenues are --, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $202.1M. Replimune Group, Inc.'s net income of -$70.9M is lower than Corcept Therapeutics, Inc.'s net income of $23.9M. Notably, Replimune Group, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 52.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group, Inc. is -- versus 6.77x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals, Inc. has a net margin of -- compared to Replimune Group, Inc.'s net margin of 34.53%. Replimune Group, Inc.'s return on equity of -92.13% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 25.2%.

Replimune Group, Inc. has a consensus price target of $12.86, signalling upside risk potential of 52.88%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.00 which suggests that it could grow by 37.71%. Given that Replimune Group, Inc. has higher upside potential than Catalyst Pharmaceuticals, Inc., analysts believe Replimune Group, Inc. is more attractive than Catalyst Pharmaceuticals, Inc..

Replimune Group, Inc. has a beta of 0.738, which suggesting that the stock is 26.18% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.667, suggesting its less volatile than the S&P 500 by 33.264%.

Replimune Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Replimune Group, Inc. quarterly revenues are --, which are smaller than Catalyst Pharmaceuticals, Inc. quarterly revenues of $152.6M. Replimune Group, Inc.'s net income of -$70.9M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.7M. Notably, Replimune Group, Inc.'s price-to-earnings ratio is -- while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group, Inc. is -- versus 5.30x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phathom Pharmaceuticals, Inc. has a net margin of -- compared to Replimune Group, Inc.'s net margin of -36.73%. Replimune Group, Inc.'s return on equity of -92.13% beat Phathom Pharmaceuticals, Inc.'s return on equity of --.

Replimune Group, Inc. has a consensus price target of $12.86, signalling upside risk potential of 52.88%. On the other hand Phathom Pharmaceuticals, Inc. has an analysts' consensus of $23.70 which suggests that it could grow by 109%. Given that Phathom Pharmaceuticals, Inc. has higher upside potential than Replimune Group, Inc., analysts believe Phathom Pharmaceuticals, Inc. is more attractive than Replimune Group, Inc..

Replimune Group, Inc. has a beta of 0.738, which suggesting that the stock is 26.18% less volatile than S&P 500. In comparison Phathom Pharmaceuticals, Inc. has a beta of 0.609, suggesting its less volatile than the S&P 500 by 39.105%.

Replimune Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phathom Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group, Inc. pays -- of its earnings as a dividend. Phathom Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Replimune Group, Inc. quarterly revenues are --, which are smaller than Phathom Pharmaceuticals, Inc. quarterly revenues of $57.6M. Replimune Group, Inc.'s net income of -$70.9M is lower than Phathom Pharmaceuticals, Inc.'s net income of -$21.1M. Notably, Replimune Group, Inc.'s price-to-earnings ratio is -- while Phathom Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group, Inc. is -- versus 4.80x for Phathom Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

REGENXBIO, Inc. has a net margin of -- compared to Replimune Group, Inc.'s net margin of -221.34%. Replimune Group, Inc.'s return on equity of -92.13% beat REGENXBIO, Inc.'s return on equity of -95.82%.

Replimune Group, Inc. has a consensus price target of $12.86, signalling upside risk potential of 52.88%. On the other hand REGENXBIO, Inc. has an analysts' consensus of $27.82 which suggests that it could grow by 226.12%. Given that REGENXBIO, Inc. has higher upside potential than Replimune Group, Inc., analysts believe REGENXBIO, Inc. is more attractive than Replimune Group, Inc..

Replimune Group, Inc. has a beta of 0.738, which suggesting that the stock is 26.18% less volatile than S&P 500. In comparison REGENXBIO, Inc. has a beta of 1.137, suggesting its more volatile than the S&P 500 by 13.687%.

Replimune Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. REGENXBIO, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group, Inc. pays -- of its earnings as a dividend. REGENXBIO, Inc. pays out -- of its earnings as a dividend.

Replimune Group, Inc. quarterly revenues are --, which are smaller than REGENXBIO, Inc. quarterly revenues of $30.3M. Replimune Group, Inc.'s net income of -$70.9M is lower than REGENXBIO, Inc.'s net income of -$67.1M. Notably, Replimune Group, Inc.'s price-to-earnings ratio is -- while REGENXBIO, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group, Inc. is -- versus 2.55x for REGENXBIO, Inc.. Usually stocks with elevated PS ratios are considered overvalued.